CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application

References

• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Linch DC, Devereux S. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol. 108(4), 817–824 (2000).
   Google Scholar
• Draube A, Klein-González N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 6(4), e18801 (2011).
   PubMed Web of Science ®Google Scholar
• Martín-Fontecha A, Sebastiani S, Höpken UE et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198(4), 615–621 (2003).
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157(4), 1406–1414 (1996).
   PubMed Web of Science ®Google Scholar
• Hackstein H, Morelli AE, Thomson AW. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22(8), 437–442 (2001).
   PubMed Web of Science ®Google Scholar
• Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2(3), 151–161 (2002).
   PubMed Web of Science ®Google Scholar
• Barrat-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-dervied dendritic cells in mokeys: implications for dendritic cell-based vaccines. J. Immunol. 164(5), 2487–2495 (2000).
   Google Scholar
• Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ. Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Infect. Immun. 67(2), 789–793 (1999).
   Google Scholar
• Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents 32(3), 199–206 (2008).
   PubMed Web of Science ®Google Scholar
• Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 265(5177), 1385–1387 (1994).
   PubMed Web of Science ®Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type B conjugate vaccines. Immunology 113(2), 163–174 (2004).
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Sperling AI, Cooke MP et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153(5), 1990–1997 (1994).
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177(4), 925–935 (1993).
   PubMed Web of Science ®Google Scholar
• Evans DE, Munks MW, Purkerson JM, Parker DC. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J. Immunol. 164(2), 688–697 (2000).
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Mohler KM, Shanebeck KD et al. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur. J. Immunol. 24(1), 116–123 (1994).
   PubMed Web of Science ®Google Scholar
• Faassen AE, Dalke DP, Berton MT, Warren WD, Pierce SK. CD40–CD40 ligand interactions stimulate B cell antigen processing. Eur. J. Immunol. 25(12), 3249–3255 (1995).
   Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357–368 (2008).
   PubMed Web of Science ®Google Scholar
• Banchereau J, de Paoli P, Vallé A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251(4989), 70–72 (1991).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature 353(6345), 678–679 (1991).
   PubMed Web of Science ®Google Scholar
• Neron S, Nadeau PJ, Darveau A, Leblanc JF. Tuning of CD40–CD154 interactions in human B lymphocyte activation: a broad array of in vitro models for a complex in vivo situation. Arch. Immunol. Ther. Exp. (Warzs.) 59(1), 25–40 (2011).
   PubMed Web of Science ®Google Scholar
• Yoon SH, Cho HI, Kim TG. Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro. Exp. Mol. Med. 37(6), 567–574 (2005).
   Google Scholar
• Schultze JL, Cardoso AA, Freeman GJ et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl Acad. Sci. USA 92(18), 8200–8204 (1995).
   PubMed Web of Science ®Google Scholar
• Fournel S, Wieckowski S, Sun W et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat. Chem. Biol. 1(7), 377–382 (2005).
   PubMed Web of Science ®Google Scholar
• Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. Cytotherapy 7(1), 62–73 (2005).
   Web of Science ®Google Scholar
• Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp. Mol. Pathol. 80(3), 252–261 (2006).
   Google Scholar
• Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100(11), 2757–2765 (1997).
   PubMed Web of Science ®Google Scholar
• Liebig TM, Fiedler A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Murine model of CD40-activation of B cells. J. Vis. Exp. 37, pii: 1734 (2010).
   Google Scholar
• Liebig TM, Fiedler A, Zoghi S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon MS. Generation of human CD40-activated B cells. J. Vis. Exp. 32, pii: 1373 (2009).
   Google Scholar
• Mayr C, Speicher MR, Kofler DM et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107(2), 742–751 (2006).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99(9), 3319–3325 (2002).
   PubMed Web of Science ®Google Scholar
• Wiesner M, Zentz C, Mayr C et al. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3(1), e1464 (2008).
   PubMed Web of Science ®Google Scholar
• Tretter T, Venigalla RK, Eckstein V et al. Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood 112(12), 4555–4564 (2008).
   PubMedGoogle Scholar
• Tu W, Lau YL, Zheng J et al. Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood 112(6), 2554–2562 (2008).
   Google Scholar
• Shimabukuro-Vornhagen A, Kondo E, Liebig T, von Bergwelt-Baildon M. Activated human B cells: stimulatory or tolerogenic antigen-presenting cells? Blood 114(3), 746–747; author reply 747 (2009).
   Google Scholar
• Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J. Immunol. 169(4), 2164–2171 (2002).
   PubMed Web of Science ®Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63(11), 2836–2843 (2003).
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103(6), 2046–2054 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 124(1), 129–140 (2008).
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Zhao Q et al. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: a preliminary approach for anti-HBV immunotherapy. Virol. J. 7(1), 370 (2010).
   Google Scholar
• Shen S, Xu Z, Qian X, Ding Y, Yu L, Liu B. Autogeneic RNA-electroporated CD40-ligand activated B-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo. Exp. Oncol. 29(2), 137–143 (2007).
   Google Scholar
• von Bergwelt-Baildon M, Schultze JL, Maecker B et al. CD40 stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63(11), 2836–2543 (2003).
   Google Scholar
• Theurich S, Malcher J, Becker HJ et al. Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells. Blood 118(22), 5979–5980 (2011).
   Google Scholar
• Liljedahl M, Winqvist O, Surh CD et al. Altered antigen presentation in mice lacking H2-O. Immunity 8(2), 233–243 (1998).
   PubMedGoogle Scholar
• von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3(11), 867–878 (2003).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107(7), 2786–2789 (2006).
   PubMed Web of Science ®Google Scholar
• Guo S, Xu J, Denning W, Hel Z. Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene Ther. 16(11), 1300–1313 (2009).
   Google Scholar
• Klein-Gonzalez N, Balkow S, Kondo E et al. CD40-activated B-cells migrate towards secondary lymphoid organs and interact dynamically with T-cells. Presented at: 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 21–24 March 2010.
   Google Scholar
• Gunzer M, Weishaupt C, Hillmer A et al. A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo. Blood 104(9), 2801–2809 (2004).
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Yang J, Hermans IF, Ronchese F. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand. J. Immunol. 60(6), 543–551 (2004).
   PubMed Web of Science ®Google Scholar
• Liebig T, Shimabukuro-Vornhagen A, Samir-Ghali, von Bergwelt-Baildon M. In vivo evaluation of a CD40-activated B cell-based tumor vaccine for use in cellular immunotherapy. Presented at: CIMT 9th Annual Meeting, Mainz, Germany, 25–27 May 2011.
   Google Scholar
• Sabat R, Grütz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21(5), 331–344 (2010).
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93(5), 1634–1642 (1999).
   PubMed Web of Science ®Google Scholar
• Yang L. TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. Curr. Mol. Med. 10(4), 374–380 (2010).
   PubMedGoogle Scholar
• Geissmann F, Revy P, Regnault A et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162(8), 4567–4575 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Ther. 7(4), 449–460 (2007).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941–952 (2004).
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-ß, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 31, 47 (2012).
   Google Scholar
• Sorenmo KU, Krick E, Coughlin CM et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS ONE 6(8), e24167 (2011).
   PubMed Web of Science ®Google Scholar
• Kondo E, Maecker B, Weihrauch MR et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin. Cancer Res. 14(20), 6574–6579 (2008).
   PubMed Web of Science ®Google Scholar
• Li Q, Lao X, Pan Q et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17(15), 4987–4995 (2011).
   PubMed Web of Science ®Google Scholar
• Kugler A, Seseke F, Thelen P et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. 82(4), 487–493 (1998).
   PubMedGoogle Scholar
• Naito M, Hainz U, Burkhardt UE et al. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol. Immunother. 62(2), 347–357 (2013).
   Google Scholar
• Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J. Immunother. 32(2), 157–160 (2009).
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Melenhorst JJ, El Ouriaghli F et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin. Cancer Res. 11(12), 4495–4503 (2005).
   PubMedGoogle Scholar
• Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int. J. Cancer 115(2), 333–336 (2005).
   PubMedGoogle Scholar